Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder

NCT03292952 is registered in ClinicalTrials.gov with Zevra Therapeutics as lead sponsor.

NCT NCT03292952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03292952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Dose-Optimized, Double-Blind, Randomized, Placebo-Controlled, Parallel Efficacy Laboratory Classroom Study With KP415 in Children With Attention-Deficit/Hyperactivity Disorder
Lead sponsor
Zevra Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
December 20, 2017
Completion date
May 16, 2018
Enrollment
155 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adhd